Drug intelligence / Profile preview

41D12 CAR-T

Development stage: Preclinical
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

**41D12 CAR-T** is a type of chimeric antigen receptor T-cell (CAR-T) therapy. It targets the CD70 antigen, which is highly expressed in renal cell carcinoma (RCC) tumors. This therapy involves genetically engineering T cells to recognize and destroy cancer cells expressing the CD70 antigen. The mechanism of action involves the CAR-T cells binding to the CD70 antigen on cancer cells, leading to their destruction.

Targets

CD70 (Cluster of Differentiation 70)

Beyond the preview

Go deeper on 41D12 CAR-T.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 41D12 CAR-T.

Explore the full profile